Acurx Pharmaceuticals Posts Earnings Results, Beats Expectations By 0.06 EPS
ACXP Stock | USD 1.15 0.01 0.88% |
Slightly above 62% of Acurx Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Acurx Pharmaceuticals LLC suggests that many traders are alarmed. Acurx Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Acurx Pharmaceuticals LLC. Many technical investors use Acurx Pharmaceuticals LLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Acurx |
Acurx Pharmaceuticals announced its quarterly earnings results on Tuesday. The company reported EPS for the quarter, beating the consensus estimate of by 0.06, Zacks reports. During the same period in the prior year, the firm posted earnings per share. Acurx Pharmaceuticals Trading Down 1.1 percent NASDAQ ACXP
Read at thelincolnianonline.com
Acurx Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Acurx Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Acurx Pharmaceuticals Fundamental Analysis
We analyze Acurx Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acurx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acurx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Acurx Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Acurx Pharmaceuticals LLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acurx Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Acurx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acurx Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Acurx Pharmaceuticals Related Equities
CADL | Candel Therapeutics | 7.14 | ||||
MNPR | Monopar Therapeutics | 6.43 | ||||
MLYS | Mineralys Therapeutics, | 4.71 | ||||
RZLT | Rezolute | 4.18 | ||||
ADAG | Adagene | 4.05 | ||||
ACRV | Acrivon Therapeutics, | 2.31 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
SILO | Silo Pharma | 1.15 | ||||
PMVP | Pmv Pharmaceuticals | 0.63 | ||||
LUMO | Lumos Pharma | 0.46 | ||||
ANTX | AN2 Therapeutics | 1.44 | ||||
AVTE | Aerovate Therapeutics | 1.49 |
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.